Fifth Circuit Halts FDA Mail-Order Abortion Pills
A federal appeals court temporarily reinstates in-person requirements for abortion medication mifepristone, striking down FDA rules and restoring medical supervision standards across the United States.
A federal appeals court temporarily reinstated nationwide requirements that women obtain abortion medication mifepristone only in person, halting the FDA's attempt to bypass Congress and eliminate safety protocols through administrative fiat. The Fifth Circuit Court of Appeals unanimously stayed the FDA's 2023 regulation on May 1, immediately ending mail-order distribution of the drug used in two-thirds of U.S. abortions and restoring the medical supervision standards the agency dismantled.
The ruling stops what Judge Stuart Kyle Duncan labeled "a textbook example of arbitrary and capricious agency action." In an 18-page opinion, the three-judge panel found the FDA systematically removed safety protocols, eliminated adverse-event reporting requirements, then used the resulting data vacuum to justify mail-order expansion. The court determined this circular logic violated federal law.
Louisiana led the challenge, arguing the FDA's policy facilitated nearly 1,000 illegal abortions monthly within its borders while forcing taxpayers to cover $92,000 in Medicaid costs for emergency complications. Judge Duncan wrote that "every abortion facilitated by the FDA's action cancels Louisiana's ban on medical abortion and undermines its policy that 'every unborn child is human being from the moment of conception and is, therefore, a legal person.'"
The FDA itself conceded its 2023 Risk Evaluation and Mitigation Strategy was "marred by 'procedural deficits' and a 'lack of adequate consideration.'" Agency officials told the court they remain unable to complete their safety review because they're still collecting data years later. This admission proved decisive, with Judge Duncan noting "the public interest is not served by perpetuating a medical practice whose safety the agency admits was inadequately studied."
Progressive organizations immediately framed the decision as an attack on reproductive rights, dismissing the medical implications for both elective and miscarriage care. "Anti-abortion politicians have just made it much harder for people everywhere in the country to get a medication that abortion and miscarriage patients have been safely using for more than 25 years," said Julia Kaye of the ACLU Reproductive Freedom Project.
That absolutist stance overlooks the FDA's own safety deficiencies. The agency removed mandatory reporting for serious complications in 2016, then cited the absence of new data as justification for eliminating in-person dispensing. "It's unreasonable for an agency to eliminate a reporting requirement for a thing and then use the resulting absence of data to support its decision," Judge Duncan wrote.
The ruling affects all patients using mifepristone, including women managing early miscarriages who previously accessed the drug through telehealth. More than 1 in 4 abortions nationwide were provided via telehealth in 2025, according to WeCount data from the Society of Family Planning. Medication abortions accounted for 63 percent of all U.S. abortions in 2023.
Manufacturers Danco Laboratories and GenBioPro rushed to the Supreme Court on May 2, filing emergency motions to block the stay. GenBioPro warned of "regulatory chaos" and argued patients nationwide face immediate confusion about what's permitted. The high court now confronts a constitutional showdown over FDA authority limits.
Carol Tobias of the National Right to Life Committee countered that "women deserve better than an abortion-by-mail system that prioritizes ideology over safety." Louisiana Attorney General Liz Murrill celebrated the ruling, stating "the Biden abortion cartel facilitated the deaths of thousands of Louisiana babies through illegal mail-order abortion pills."
The case underscores a broader battle against administrative overreach. The FDA expanded access through executive fiat following President Biden's 2022 order directing agencies to "expand access to medication abortion" after the Supreme Court returned abortion regulation to states. This regulatory end-run bypassed congressional authority and state sovereignty.
Health care providers now face immediate implementation challenges. The stay reinstates protocols requiring mifepristone distribution at licensed medical facilities, affecting even states where abortion remains legally protected. Misoprostol, the second drug in the regimen, remains unaffected but is less effective alone.
The Supreme Court's response will determine whether the administrative state can unilaterally override state laws and safety standards. With the FDA unable to defend its own regulations and still collecting safety data years later, the Fifth Circuit found judicial intervention essential to protect medical standards and state sovereignty.